Technology

Our platform and its key advantages

VaxEquity’s next-generation RNA platform addresses many of the shortfalls associated with using modified and unmodified RNA

VaxEquity’s next-generation RNA platform addresses many of the shortfalls associated with using modified and unmodified RNA Traditional mRNA vaccines and therapeutics require relatively high doses to achieve an effect.

This is because protein expression is directly proportional to the number of RNA transcripts administered.

  • VaxEquity uses self-amplifying RNA which results in generation of multiple RNA copies in the call and thus greatly enhanced protein expression.
  • In addition, VaxEquity, using our proprietary technology platform, can modify the RNA to include elements (innate inhibitory proteins, IIPs) that selectively suppress the innate immune response, thereby preventing the host cell from shutting down RNA replication.
  • Use of different IIPs allows for variable control over the innate immune system making VaxEquity’s approach highly tuneable.
VaxEquity’s strategy of administration of saRNA delivering an IIP gives significantly enhanced expression of vaccine antigens or therapeutic proteins. It is highly scalable and stable, and with lower doses being required, more doses can be produced and delivered at a lower price per unit.

Vxt technology 2x

Key Advantages

  • Potential to be effective at a lower dose and with less frequent dosing

  • Potential in a wide range of therapeutic areas

  • Flexibility ensures we can design, develop and manufacture rapidly and at scale

  • Strong IP position with patents covering our platform and its components

Get in touch

Thank you for your message

We have recieved your message and will get back to your shortly.